Similar articles

• Enfuvirtide antiviral activity despite rebound viremia and resistance mutations: fitness tampering or a case of persistent braking on entering?

  Morse C, Maldarelli F. Morse C, et al. J Infect Dis. 2007 Feb 1;195(3):318-21. doi: 10.1086/510539. Epub 2006 Dec 21. J Infect Dis. 2007. PMID: 17205468 Review. No abstract available.
• Enfuvirtide for prophylaxis against HIV infection.

  Cuzin L, Alvarez M. Cuzin L, et al. N Engl J Med. 2003 Nov 27;349(22):2169-70; author reply 2169-70. doi: 10.1056/NEJM200311273492218. N Engl J Med. 2003. PMID: 14645649 No abstract available.
• Drug profile: enfuvirtide (Fuzeon, ENF, T-20).

  Pham PA. Pham PA. Hopkins HIV Rep. 2003 May;15(3):1-2. Hopkins HIV Rep. 2003. PMID: 12809104 No abstract available.
• [Enfuvirtide. Two injections per day for HIV].

  Taéron C. Taéron C. Rev Infirm. 2004 Oct;(104):35-6. Rev Infirm. 2004. PMID: 15581312 French. No abstract available.
• [Enfuvirtide, mechanism of action and pharmacological properties].

  Kapić E, Becić F, Zvizdić S. Kapić E, et al. Med Arh. 2005;59(5):313-6. Med Arh. 2005. PMID: 16134757 Review. Bosnian.